人表皮生长因子受体2低表达乳腺癌：过去、现在和未来

HER2-low expression breast cancer: past, present and future

摘要:

乳腺癌为全球高发病率的恶性肿瘤之一，临床主要依据人表皮生长因子受体2（HER2）及激素受体（HR）的不同表达情况来划分其分子亚型，根据分型选择进一步诊疗方案。既往乳腺癌患者HER2诊断标准仅分为HER2阳性和HER2阴性，但随着治疗手段的发展和进步，HER2分型的细化也越来越受到关注，HER2低表达这一概念也在2021年首次被引入乳腺癌诊疗指南。本文旨在对HER2低表达乳腺癌患者的临床特征、治疗现状及对未来的展望三个方面进行系统性综述，以期更好地理解“HER2低表达”乳腺癌亚型的临床特征，为乳腺癌的诊断和精准治疗提供科学依据。

Abstract:

Breast cancer is one of the malignant tumors with high incidence in the world. Clinical practice primarily relies on the different expression of human epidermal growth factor receptor 2 (HER2) and estrogen receptor (HR) to determine its molecular subtypes, which further guide the selection of treatment options. Previous diagnostic criteria for HER2 in breast cancer patients just classified them as HER2 positive or HER2 negative. However, with the development and advancement of treatment methods, there is increasing attention on the refinement of HER2 subtyping. The concept of HER2 low-expression was also introduced into the breast cancer diagnosis and treatment guidelines in 2021 for the first time. This article aims to conduct a systematic review on the clinical characteristics, treatment status, and future prospects of patients with HER2-low expression breast cancer, in order to better understand the clinical characteristics of the subtype "HER2-low expression". It is intended to provide a scientific foundation for the diagnose and precise treatment of breast cancer patients.